Cerebellum GP LLC Buys 241 Shares of Cooper Companies Inc (NYSE:COO)

Cerebellum GP LLC grew its stake in shares of Cooper Companies Inc (NYSE:COO) by 22.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,307 shares of the medical device company’s stock after acquiring an additional 241 shares during the period. Cerebellum GP LLC’s holdings in Cooper Companies were worth $388,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Nuveen Asset Management LLC increased its holdings in Cooper Companies by 31,545.4% during the second quarter. Nuveen Asset Management LLC now owns 342,087 shares of the medical device company’s stock valued at $115,246,000 after buying an additional 341,006 shares during the period. Swedbank purchased a new position in Cooper Companies during the second quarter valued at approximately $100,362,000. Prudential Financial Inc. increased its holdings in Cooper Companies by 330.9% during the second quarter. Prudential Financial Inc. now owns 297,402 shares of the medical device company’s stock valued at $100,192,000 after buying an additional 228,380 shares during the period. Vanguard Group Inc. increased its holdings in Cooper Companies by 4.3% during the second quarter. Vanguard Group Inc. now owns 5,566,546 shares of the medical device company’s stock valued at $1,875,314,000 after buying an additional 227,435 shares during the period. Finally, Marshall Wace North America L.P. increased its holdings in Cooper Companies by 115.1% during the second quarter. Marshall Wace North America L.P. now owns 420,179 shares of the medical device company’s stock valued at $141,554,000 after buying an additional 224,844 shares during the period. 95.82% of the stock is owned by hedge funds and other institutional investors.

NYSE COO opened at $295.15 on Wednesday. The firm’s fifty day simple moving average is $301.11 and its two-hundred day simple moving average is $309.97. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39. Cooper Companies Inc has a 12-month low of $228.65 and a 12-month high of $344.32. The firm has a market capitalization of $14.57 billion, a P/E ratio of 24.66, a P/E/G ratio of 2.31 and a beta of 0.91.

Cooper Companies (NYSE:COO) last released its quarterly earnings results on Thursday, August 29th. The medical device company reported $3.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.16 by $0.07. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. The business had revenue of $679.40 million for the quarter, compared to analyst estimates of $687.60 million. During the same period in the previous year, the company earned $3.00 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, sell-side analysts predict that Cooper Companies Inc will post 12.32 earnings per share for the current fiscal year.

In other Cooper Companies news, Director Allan E. Rubenstein sold 1,335 shares of Cooper Companies stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $299.61, for a total value of $399,979.35. Following the transaction, the director now directly owns 3,591 shares of the company’s stock, valued at $1,075,899.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is currently owned by insiders.

Several equities analysts recently issued reports on COO shares. Wells Fargo & Co lifted their price objective on shares of Cooper Companies from $356.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. KeyCorp cut their price objective on shares of Cooper Companies from $351.00 to $348.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Piper Jaffray Companies set a $360.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, August 30th. ValuEngine lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Tuesday, September 10th. Finally, Raymond James reissued a “buy” rating on shares of Cooper Companies in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $326.00.

Cooper Companies Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Read More: Most Volatile Stocks

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).

Institutional Ownership by Quarter for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.